Alumis
Alumis Inc. is a precision medicines company focused on transforming the lives of patients with autoimmune diseases. They are hiring for a senior role to lead statistical programming efforts in drug development projects, ensuring quality and regulatory compliance.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2021
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for immune-mediated diseases. It advances a late-stage portfolio of next-generation targeted programs — including TYK2 and IGF-1R pathway efforts and assets such as envudeucitinib and lonigutamab — aimed at conditions like psoriasis, SLE and thyroid eye disease. The company combines integrated scientific insights with a proprietary data‑analytics platform to guide therapeutic development and clinical trial strategy. Alumis emphasizes patient-centered development, offering resources and conducting trials to translate its medicines into meaningful improvements in patients’ lives.
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead
2 days ago
Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026
20 hours ago
Raymond James initiates Alumis stock coverage citing psoriasis drug potential
2 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Alumis.
32% above the average for this role
Watkins Advises on Alumis’ Upsized US$345 Million Public Offering of Common Stock
Jan 9, 2026
Director/Sr. Director, Statistical Programming
Artiva Biotherapeutics
Senior Manager, Statistical Programming
Immunovant, Inc.
Director, Statistical Programming
CSL
Associate Director, Statistical Programming
Revolution Medicines
Sr. Principal Analyst, Statistical Programming
lifelancer
Director, Statistical Programming
Seaport Therapeutics